vs
ANI PHARMACEUTICALS INC（ANIP）とASTEC INDUSTRIES INC（ASTE）の財務データ比較。上の社名をクリックして会社を切り替えられます
ASTEC INDUSTRIES INCの直近四半期売上が大きい（$396.3M vs $247.1M、ANI PHARMACEUTICALS INCの約1.6倍）。ANI PHARMACEUTICALS INCの純利益率が高く（11.1% vs 0.3%、差は10.8%）。ANI PHARMACEUTICALS INCの前年同期比売上増加率が高い（29.6% vs 20.3%）。ASTEC INDUSTRIES INCの直近四半期フリーキャッシュフローが多い（$32.6M vs $29.1M）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs 7.1%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
ASTECは香港に本社を置く国際的な電子企業で、主に電源装置と電力変換ハードウェアを製造しています。コンピュータシステム用電源の世界的な主要サプライヤーの一つで、一時期は世界最大の電源メーカーでした。
ANIP vs ASTE — 直接比較
損益計算書 — Q4 FY2025 vs Q1 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $396.3M |
| 純利益 | $27.5M | $1.3M |
| 粗利率 | — | 25.0% |
| 営業利益率 | 14.1% | 2.3% |
| 純利益率 | 11.1% | 0.3% |
| 売上前年比 | 29.6% | 20.3% |
| 純利益前年比 | 367.5% | — |
| EPS（希薄化後） | $1.14 | $0.06 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | — | $396.3M | ||
| Q4 25 | $247.1M | $400.6M | ||
| Q3 25 | $227.8M | $350.1M | ||
| Q2 25 | $211.4M | $330.3M | ||
| Q1 25 | $197.1M | $329.4M | ||
| Q4 24 | $190.6M | $359.0M | ||
| Q3 24 | $148.3M | $291.4M | ||
| Q2 24 | $138.0M | $345.5M |
| Q1 26 | — | $1.3M | ||
| Q4 25 | $27.5M | $12.0M | ||
| Q3 25 | $26.6M | $-4.2M | ||
| Q2 25 | $8.5M | $16.7M | ||
| Q1 25 | $15.7M | $14.3M | ||
| Q4 24 | $-10.3M | $21.1M | ||
| Q3 24 | $-24.2M | $-6.2M | ||
| Q2 24 | $-2.3M | $-14.0M |
| Q1 26 | — | 25.0% | ||
| Q4 25 | — | 27.3% | ||
| Q3 25 | — | 24.1% | ||
| Q2 25 | — | 26.7% | ||
| Q1 25 | — | 28.1% | ||
| Q4 24 | — | 28.7% | ||
| Q3 24 | — | 22.9% | ||
| Q2 24 | — | 23.5% |
| Q1 26 | — | 2.3% | ||
| Q4 25 | 14.1% | 5.7% | ||
| Q3 25 | 15.9% | 0.3% | ||
| Q2 25 | 6.6% | 6.5% | ||
| Q1 25 | 13.3% | 6.2% | ||
| Q4 24 | -2.3% | 9.7% | ||
| Q3 24 | -13.8% | -2.5% | ||
| Q2 24 | 3.7% | -3.1% |
| Q1 26 | — | 0.3% | ||
| Q4 25 | 11.1% | 3.0% | ||
| Q3 25 | 11.7% | -1.2% | ||
| Q2 25 | 4.0% | 5.1% | ||
| Q1 25 | 8.0% | 4.3% | ||
| Q4 24 | -5.4% | 5.9% | ||
| Q3 24 | -16.3% | -2.1% | ||
| Q2 24 | -1.7% | -4.1% |
| Q1 26 | — | $0.06 | ||
| Q4 25 | $1.14 | $0.52 | ||
| Q3 25 | $1.13 | $-0.18 | ||
| Q2 25 | $0.36 | $0.72 | ||
| Q1 25 | $0.69 | $0.62 | ||
| Q4 24 | $-0.45 | $0.92 | ||
| Q3 24 | $-1.27 | $-0.27 | ||
| Q2 24 | $-0.14 | $-0.61 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | — |
| 総負債低いほど良い | — | $365.5M |
| 株主資本純資産 | $540.7M | $678.1M |
| 総資産 | $1.4B | $1.4B |
| 負債/資本比率低いほどレバレッジが低い | — | 0.54× |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | — | ||
| Q4 25 | $285.6M | $74.1M | ||
| Q3 25 | $262.6M | $71.8M | ||
| Q2 25 | $217.8M | $91.6M | ||
| Q1 25 | $149.8M | $95.4M | ||
| Q4 24 | $144.9M | $93.8M | ||
| Q3 24 | $145.0M | $58.9M | ||
| Q2 24 | $240.1M | $68.4M |
| Q1 26 | — | $365.5M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $678.1M | ||
| Q4 25 | $540.7M | $681.7M | ||
| Q3 25 | $505.8M | $668.9M | ||
| Q2 25 | $436.8M | $674.9M | ||
| Q1 25 | $418.6M | $653.2M | ||
| Q4 24 | $403.7M | $637.8M | ||
| Q3 24 | $405.9M | $631.4M | ||
| Q2 24 | $455.8M | $633.3M |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $1.4B | $1.4B | ||
| Q3 25 | $1.4B | $1.3B | ||
| Q2 25 | $1.3B | $1.1B | ||
| Q1 25 | $1.3B | $1.1B | ||
| Q4 24 | $1.3B | $1.0B | ||
| Q3 24 | $1.3B | $1.1B | ||
| Q2 24 | $920.8M | $1.1B |
| Q1 26 | — | 0.54× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $20.7M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | $32.6M |
| FCFマージンFCF / 売上 | 11.8% | 8.2% |
| 設備投資強度設備投資 / 売上 | 0.5% | — |
| キャッシュ転換率営業CF / 純利益 | 1.10× | 15.92× |
| 直近12ヶ月FCF直近4四半期 | $171.4M | $36.7M |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | $20.7M | ||
| Q4 25 | $30.4M | $36.1M | ||
| Q3 25 | $44.1M | $-8.1M | ||
| Q2 25 | $75.8M | $12.9M | ||
| Q1 25 | $35.0M | $20.5M | ||
| Q4 24 | $15.9M | $36.6M | ||
| Q3 24 | $12.5M | $22.5M | ||
| Q2 24 | $17.4M | $10.9M |
| Q1 26 | — | $32.6M | ||
| Q4 25 | $29.1M | $7.4M | ||
| Q3 25 | $38.0M | $-12.3M | ||
| Q2 25 | $71.8M | $9.0M | ||
| Q1 25 | $32.5M | $16.6M | ||
| Q4 24 | $13.5M | $32.1M | ||
| Q3 24 | $7.7M | $19.9M | ||
| Q2 24 | $13.0M | $3.3M |
| Q1 26 | — | 8.2% | ||
| Q4 25 | 11.8% | 1.8% | ||
| Q3 25 | 16.7% | -3.5% | ||
| Q2 25 | 34.0% | 2.7% | ||
| Q1 25 | 16.5% | 5.0% | ||
| Q4 24 | 7.1% | 8.9% | ||
| Q3 24 | 5.2% | 6.8% | ||
| Q2 24 | 9.4% | 1.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 7.2% | ||
| Q3 25 | 2.7% | 1.2% | ||
| Q2 25 | 1.9% | 1.2% | ||
| Q1 25 | 1.3% | 1.2% | ||
| Q4 24 | 1.3% | 1.3% | ||
| Q3 24 | 3.2% | 0.9% | ||
| Q2 24 | 3.2% | 2.2% |
| Q1 26 | — | 15.92× | ||
| Q4 25 | 1.10× | 3.01× | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | 0.77× | ||
| Q1 25 | 2.23× | 1.43× | ||
| Q4 24 | — | 1.73× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
ASTE
| Infrastructure Solutions | $237.0M | 60% |
| Materials Solutions | $159.3M | 40% |
